Minimally Invasive Healthcare (00853) fell by more than 4%, and its stock price has fallen by more than 37% during the year. As of press release, it fell 4.17% to HK$5.28, with a turnover of HK$20.3597 million.
The Zhitong Finance App learned that Minimally Invasive Healthcare (00853) fell by more than 4%, and its stock price had already fallen by more than 37% during the year. As of press release, it fell 4.17% to HK$5.28, with a turnover of HK$20.3597 million.
According to the news, Minimally Invasive Healthcare previously announced that it has obtained 150 million US dollars (over 1 billion yuan) of convertible term loan financing from Gao Lin and others. According to the agreement, Minimally Invasive Healthcare promised to lose no more than 275 million US dollars by the end of 2024, no more than 100 million US dollars in 2025, no more than 55 million US dollars at the end of 2025, no less than 45 million US dollars in mid-2026, and no less than 90 million US dollars by the end of 2026.
Nomura believes that the exercise price of US$150 million is HK$7.46, while the company must meet its performance targets. Otherwise, it will be necessary to repay the $50 million loan from High House Capital in advance. The bank believes that the situation may improve in the short term, but it will still be difficult in the long run. Financial reports show that Minimally Invasive Healthcare lost US$649 million for the full year of 2023, and the extent of the loss increased by 10.4%. Losses were recorded for 4 consecutive years, with only $1,019 million in cash and equivalent at the end of the period.